Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular car...

(3:12)

RATIONALE-305: tislelizumab + chemo vs placebo +chemo in advanced GC/GEJC

(27)

RATIONALE-306: tislelizumab and chemotherapy in ESCC

(4:3)

QoL analyses from RATIONALE-301 of tislelizumab vs sorafenib in HCC

(2:1econd)

Chapter 22. Tislelizumab

(7:)

RATIONALE-306: Asian subgroup of 1L tislelizumab + chemo vs chemo alone for esophageal SCC

(3:9)

Sitravatinib + tislelizumab in advanced BTC after systemic treatment failure: Phase II study

(1:48)

一个视频深入分析下美国FDA拒绝国产抗癌药信迪利单抗上市的这件事情

(12:14)

|| Webinar - Lessons from ASCO 2024 DEEP DIVE GI Cancers || 11th July 2024 ||

(2:19:37)

Immunotherapy | MOA Animation

(4:18)

Tiến bộ hóa chất mới nhất 2024 điều trị ung thư phổi

(37:13)

手術期前後使用免疫治療藥物替雷利珠單抗(Tislelizumab)搭配化療 有助提升可以手術切除非小细胞肺癌治療的成績

(28:28)

Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

(1:22:29)

شرح مبسط لمفهوم Immune Checkpoint Inhibitors

(2:43)

20190413 Laura Soucek - Omomyc, el nuevo fàrmaco contra el cáncer

(31:19)

The Implications of Recent Datasets for the Current and Future Management of NSCLC EGFR Mutations

(58:19)

간세포암 치료 전략에 새로운 지평을 열다-'The Liver Week 2020' 리뷰 1-

(33:2)

Tislelizumab for R/R classical Hodgkin lymphoma

(2:42)

Tislelizumab in oesophageal cancer after systemic therapy

(7:47)

#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study

(2:30)

Yuqin Song | ASH 2018 | Tislelizumab (BGB-A317) in relapsed/refractory classical Hodgkin lymphoma

(2:11)

Immune Checkpoint Inhibitors, The Next Generation Cancer Therapy - Creative Biolabs

(2:7)

BEAT-meso: Phase III trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma

(40)

Association between TI and improved OS in myelofibrosis patients receiving momelotinib

(2:14)

Toxicities Associated with Ribociclib From MONALEESA-3 Trial

(27)

ESMO 2022: Highlights, commentary and analysis

(33:28)

Solid Tumor Pharmacy Update | Monica Quinn, PharmD

(17:43)